elsamicin A (elsamitrucin)

from actinomycete strain J907-21; structure given in first source

Also Known As:

elsamitrucin; BBM 2478A; BBM-2478A; BMY 28090; BMY-28090; Benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl-

Networked: 12 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - elsamicin A: 12

Experts

1.	Fiocchi, S C: 1 article (07/2011)
2.	Henry, C: 1 article (07/2011)
3.	Kolli, P: 1 article (07/2011)
4.	Lenaz, G: 1 article (07/2011)
5.	Rosenberg, M P: 1 article (07/2011)
6.	Selting, K A: 1 article (07/2011)
7.	Portugal, José: 1 article (11/2003)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/1994 - "This study was initiated to determine the activity of elsamitrucin in patients with previously untreated, bi-dimensionally measurable, cytologically or histologically proven, non-small cell lung cancer who were not curable by surgery. " 01/01/1994 - "Phase II study of elsamitrucin in non-small cell lung cancer." 01/01/1994 - "These results indicate that elsamitrucin when given in this dose and schedule to patients with surgically incurable non-small cell lung cancer has no activity." 04/01/1994 - "Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. " 04/01/1994 - "Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer."
2.	Neoplasms (Cancer) 07/01/2011 - "An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs." 07/01/2011 - "To determine the maximum tolerated dose (MTD), safety, and toxicity of elsamitrucin when administered to tumor-bearing dogs and to evaluate the incidence and severity of adverse events. " 07/01/1989 - "BMY-28090 administered iv at maximally tolerated doses had marginal activity against the HCT116 xenografts, producing 61% and 68% inhibition of tumor growth in two tests. " 07/01/1989 - "At maximum tolerated doses administered ip, BMY-28090 was active against the MX-1 xenograft in two of three tests, causing greater than 90% inhibition of tumor growth. " 07/01/1989 - "Following 72-hour exposures, BMY-28090 was cytotoxic for all of these cell lines with IC50 values of less than 0.02 to 3.25 micrograms/ml. BMY-28090 was evaluated for in vivo antitumor activity in a variety of experimental murine tumor and human tumor xenograft models. "
3.	Breast Neoplasms (Breast Cancer) 04/01/1994 - "To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. " 12/01/1992 - "Activity of a chartreusin analog, elsamicin A, on breast cancer cells." 04/01/1994 - "Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. " 04/01/1994 - "Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer." 12/01/1992 - "The in vitro activity of elsamicin A (ELS) was investigated compared with that of doxorubicin (DX) on two sensitive breast cancer cell lines: one estrogen receptor-positive (ER+, MCF7) and one estrogen receptor-negative (ER-, MDA-MB-231) line, and on a DX-resistant subline (MCF7DX). "
4.	Colorectal Neoplasms (Colorectal Cancer) 04/01/1994 - "Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. " 04/01/1994 - "Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer."
5.	Ovarian Neoplasms (Ovarian Cancer) 04/01/1994 - "Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. " 04/01/1994 - "Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer."

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Anti-Bacterial Agents (Antibiotics)
3.	chartreusin
4.	Topoisomerase II Inhibitors
5.	Cytostatic Agents
6.	Succinic Acid (Succinate)
7.	Lactic Acid (Lactate)
8.	Trimetrexate (JB11)
9.	Carboplatin (JM8)
10.	Salts

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)